Secondary malignancies after hematopoietic stem cell transplantation

Neoplasma

Volumn 58, Issue 1, 2011, Pages 1-8

  Roziakova, L ^a,b   Bojtarova, E ^b   Mistrik, M ^b   Mladosievicova, B ^a  

^a Comenius University ^*  (Slovakia)

^b UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Hematopoietic stem cell transplantation; Late complications; Secondary malignancies

Indexed keywords

AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CYTOGENETICS; GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; REVIEW; RISK FACTOR; SOLID TUMOR; WHOLE BODY RADIATION; BLOOD DISEASE; INCIDENCE; SECOND CANCER;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 84857387590     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_01_1     Document Type: Review

References (78)

1. MLADOSIEVIČOVÁ, B, BERNADIC M. Developing strategies for long-term follow up of cancer survivors. Bratisl Lek Listy 2002; 103: 390-392.
2. BAKER KS, DEFOR TE, BURNS LJ, RAMSAY NK, NEGLIA JP et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358. doi:10.1200/JCO.2003.05.108.
3. CHOI JH, PARK BB, SUH C, WON JH, LEE WS et al. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci 2010; 25: 523-526. doi:10.3346/jkms.2010.25.4.523.
4. SWERDLOW SH, WEBBER SA, CHADBURN A, FERRY JA. Post-transplant lymphoproliferative disorders. IN: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Sterin H, Thiele J, Vardiman Jw, editors. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues. Lyon: IARC 2008; 343-349.
5. HARRIS NL, FRIZERRA G, KNOWLES DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, editors. The World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC Press 2001: 264-269.
6. HESLOP HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008. doi:10.1182/blood-2009-07-143545.
7. Gottschalk S, ROONEY CM, HESLOP HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44. doi:10.1146/annurev.med.56.082103.104727.
8. GODT C, REGNERY A, SCHWARZE B, JUNKER K, PORSCHEN R. A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD). Z Gastroenterol 2009; 47: 283-287. doi:10.1055/s-2008-1027554.
9. TASHIRO Y, GOTO M, TAKEMOTO Y, SATO E, SHIRAHAMA H et al. Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case. Pathol Int 2006; 56: 530-537. doi:10.1111/j.1440-1827.2006.02001.x.
10. LANGE A, KLIMCZAK A, DLUBEK D, DYBKO J. B-cell lymphoproliferative syndrome and peripheral blood CD201 cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. Transplant Proc 2003; 35: 3093-3095. doi:10.1016/j.transproceed.2003.10.043.
11. HOU HA, YAO M, TANG JL, CHEN YK, KO BS et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years'experience in a single institute. Bone Marrow Transplant 2009; 43: 315-321. doi:10.1038/bmt.2008.325.
12. AISA Y, MORI T, NAKAZATO T, SUZUKI S, SUZUKI N et al. Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 2009; 11: 438-441. doi:10.1111/j.1399-3062.2009.00409.x.
13. AWAYA N, ADACHI A, MORI T, KAMATA H, NAKAHARA J et al. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblasticT-cell lymphoma. Leuk Res 2006; 30: 1059-1062. doi:10.1016/ j.leukres.2005.10.022.
14. OCHENI S, KROEGER N, ZABELINA T, SOBOTTKA I, AYUK F et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplantation 2008; 42: 181-186. doi:10.1038/bmt.2008.150.
15. MARKASZ L, STUBER G, FLABERG E, JERNBERG AG, EKSBORG S et al. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer 2006; 6: 265. doi:10.1186/1471-2407-6-265.
16. BOWER M. The management of lymphoma in the immuno-suppressed patient. Best Pract Res Clin Haematol 2002; 15: 517-532. doi:10.1053/beha.2002.0213.
17. LACASCE AS. Post-transplant lymphoproliferative disorders. Oncologist 2006; 11: 674-680. doi:10.1634/theoncologist.11-6-674.
18. LANDGREN O, GILBERT ES, RIZZO JD, SOCIÉ G, BANKS PM et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell Transplantation. Blood 2009; 113: 4992-5001. doi:10.1182/blood-2008-09-178046.
19. XU LP, HUANG XJ, LIS DH, CHEN YH, SHI HX et al. A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. Zhonghua Nie Ke Za Zhi 2007; 46: 996-999.
20. BARKER JN, MARTIN PL, COAD JE, DEFOR T, TRIGG ME et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood MarrowTransplant 2001; 7: 395-399. doi:10.1053/bbmt.2001.v7.pm11529490.
21. OKUNO K, HORIE Y, KANAI K, KATO M, KUWAMOTO S et al. Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop 2009; 49: 45-51. doi:10.3960/jslrt.49.45.
22. COHEN JM, COOPER N, CHAKRABARTI S, THOMSON K, SAMARASINGHE S et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymph 2007; 48: 256-269. doi:10.1080/10428190601059837.
23. KATAOKA K, SEO S, OTA S, TAKAHASHI T, KUROKAWA M. Positron emission tomography in the diagnosis and therapeutic monitoring of post-transplant lymphoproliferative disorder after cord blood transplantation. Bone Marrow Transplantation 2010; 45: 610-612. doi:10.1038/bmt.2009.205.
24. MEERBACH A, WUTZLER P, HÄFER R, ZINTL F, GRUHN B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008; 80: 441-454. doi:10.1002/jmv.21096.
25. MEIJER E, CORNELISSEN JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008; 15: 576-585. doi:10.1097/MOH.0b013e328311f438.
26. WANG LH, REN HY, SUN YH, QIU ZX, CEN XN et al. Quantitative monitoring of mononucleated cell Epstein-Barr virus (EBV)-DNA for predicting EBV associated lymphoproliferative disorders after stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi 2010; 31: 73-76.
27. STYCZYNSKI J, EINSELE H, GIL L, LJUNGMAN P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stemcell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383-392. doi:10.1111/j.1399-3062.2009.00411.x.
28. AHMAD I, CAU NV, KWAN J, MAAROUFI Y, MEULEMAN N et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009; 87: 1240-1245. doi:10.1097/TP.0b013e31819f1c49.
29. MOOSMANN A, BIGALKE I, TISCHER J, SCHIRRMANN L, KASTEN J et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115: 2960-2970. doi:10.1182/blood-2009-08-236356.
30. HESLOP HE, SLOBOD KS, PULE MA, HALE GA, ROUSSEAU A et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935. doi:10.1182/blood-2009-08-239186.
31. KALAYCIO M, RYBICKI L, POHLMAN B, SOBECKS R, ANDRESEN S et al. Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia. J Clin Oncol 2006; 24: 3604-3610. doi:10.1200/JCO.2006.06.0673.
32. PEDERSEN-BJERGAARD J, ANDERSEN MK, CHRIS-TIANSEN DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 3273-3279.
33. LARSON RA, LE BEAU MM. Therapy-related myeloid leu-kaemia: a model for leukemogenesis in humans. Chem Biol Interact 2005; 153-154: 187-195.
34. SCHOCH C, KERN W, SCHNITTGER S, HIDDEMANN W, HAFERLACH T. Karyotype is an independent prognostic parameter in therapy related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120-125. doi:10.1038/sj.leu.2403187.
35. DAVIES SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001; 36: 536-540. doi:10.1002/mpo.1126.
36. BLOOMFIELD CD, ARCHER KJ, MROZEK K, LILLING-TON DM, KANEKO Y et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 362-378. doi:10.1002/ gcc.10046.
37. METAYER C, CURTIS RE, VOSE J, SOBOCINSKI KA, HOROWITZ MM et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015-2023. doi:10.1182/blood-2002-04-1261.
38. MICALLEF IN, LILLINGTON DM, APOSTOLIDIS J, AMESS JA, NEAT M et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955.
39. HOSING C, MUNSELL M, YAZJI S, ANDERSSON B, COURIEL D et al. Risk of therapy-related myelodysplastic syndrome/ acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 450-459. doi:10.1093/an-nonc/mdf109.
40. ARMITAGE JO, CARBONE PP, CONNORS JM, LEVINE A, BENNETT JM et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897-906. doi:10.1200/JCO.2003.07.113.
41. BRAESS J, SCHOCH C, FIEGL M, SCHMID C, HIDDE-MANN W et al. Etiology of acute myeloid leukemia following intensive therapy for AML--relapse, secondary disease or bad luck? Leukemia 2002; 16: 2459-2462. doi:10.1038/sj.leu.2402772.
42. CHO BS, KIM HJ, EOM KS, LEE JW, MIN WS et al. A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML. Korean J Intern Med 2010; 25: 110-113. doi:10.3904/kjim.2010.25.1.110.
43. LADETTO M, VALLET S, BENEDETTI F, VITOLO U, MARTELLI M et al. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia 2006; 20: 1840-1847. doi:10.1038/sj.leu.2404346.
44. KROGER N, DAMON L, ZANDER AR, WANDT H, DERIGS G et al. Secondary acute leukemia following mitoxantrone- based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant 2003; 32: 1153-1157. doi:10.1038/sj.bmt.1704291.
45. RODENHUIS S, BONTENBAL M, BEEX LV, WAGSTAFF J, RICHEL DJ et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16. doi:10.1056/NEJMoa022794.
46. FORREST DL, HOGGE DE, NEVILL TJ, NANTEL SH, BARNETT MJ et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005; 23: 7994-8002.
47. BROWN JR, YECKES H, FRIEDBERG JW, NEUBERG D, KIM H et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 2208-2214. doi:10.1200/JCO.2005.05.158.
48. LEONE G, FIANCHI L, PAGANO L, VOSO MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 2010; 184: 39-45. doi:10.1016/j.cbi.2009.12.013.
49. KNOCHE E, MCLEOD HL, GRAUBERT TA. Phar-macogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics 2006; 7: 719-729. doi:10.2217/ 14622416.7.5.719.
50. CHAKRABORTY S, SUN CL, FRANCISCO L, SABADO M, LI L et al. Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma. J Clin Oncol 2009; 27: 791-798. doi:10.1200/ JCO.2008.17.1033.
51. HAKE CR, GRAUBERT TA, FENSKE TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplantation 2007; 39, 59-70. doi:10.1038/sj.bmt.1705547.
52. LITZOW MR, TARIMA S, PÉREZ WS, BOLWELL BJ, CAIRO MS et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115, 1850-1857. doi:10.1182/blood-2009-10-249128.
53. KRÖGER N, BRAND R, BIEZEN A, ZANDER A, DIERLAMM J et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542-549. doi:10.3324/haematol.2008.000927.
54. FENAUX P, MUFTI GJ, HELLSTROMLINDBERG E, SANTINI V, FINELLI C et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232. doi:10.1016/S1470-2045(09)70003-8.
55. RIZZO JD, CURTIS RE, SOCIÉ G, SOBOCINSKI KA, GIL-BERT E et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183. doi:10.1182/blood-2008-05-158782.
56. BHATIA S, LOUIE AD, BHATIA R, O'DONNELL MR, FUNG H et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471.
57. AU W-Y, CHAN EC, PANG A, LIE AKW, LIANG R et al. Non-hematologic malignancies after allogeneic hematopoietic stem cell transplantation: incidence and molecular monitoring. Bone Marrow Transplant 2004; 34: 981-985. doi:10.1038/sj.bmt.1704674.
58. HASEGAWA W, POND GR, RIFKIND JT, MESSNER HA, LAU A et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplantation 2005; 35, 51-55. doi:10.1038/sj.bmt.1704706.
59. SHIMADA K, YOKOZAWA T, ATSUTA Y, KOHNO A, MARUYAMA F et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005; 36: 115-121. doi:10.1038/sj.bmt.1705020.
60. GALLAGHER G, FORREST DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007; 109: 84-92. doi:10.1002/cncr.22375.
61. FRIEDRICHS B, TICHELLI A, BACIGALUPO A, RUSSELL NH, RUUTU T et al. Long-term outcome and late eff ects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11: 331-338. doi:10.1016/S1470-2045(09)70352-3.
62. HU Y-X, CUI Q, LIANG B, HUANG H: Donor-Derived Solid Malignancies after Hematopoietic Stem Cell Transplantation. Onkologie 2010; 33: 195-200. doi:10.1159/000290661.
63. DEMAROSI F, LODI G, CARRASSI, SOLIGO D, SARDELLA A. Oral malignancies following HSCT: Graft versus host disease and other risk factors. Oral Oncology 2005; 41, 865-877. doi:10.1016/j.oraloncology.2005.02.001.
64. LEISENRING W, FRIEDMAN DL, FLOWERS ME, SCHWARTZ JL, DEEG HJ et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119-1126. doi:10.1200/JCO.2005.02.7052.
65. KRUSE AL, GRÄTZ KW. Oral carcinoma after hematopoietic stem cell transplantation - a new classification based on a literature review over 30 years. Head & Neck Oncology 2009; 29: 1-6.
66. CURTIS RE, METAYER C, RIZZO JD, SOCIÉ G, SOBOCINSKI KA et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem cell transplantation: an international case-control study. Blood 2005; 105: 3802-3811. doi:10.1182/blood-2004-09-3411.
67. SCHWARTZ JL, KOPECKY KJ, MATHES RW, LEISENRING WM, FRIEDMAN DL et al. Basal Cell Skin Cancer after Total-Body Irradiation and Hematopoietic Cell Transplantation. Radiat Res 2009; 171: 155-163. doi:10.1667/RR1469.1.
68. CAVALIER M, SHMALO JA, YU M, BILLINGS SD, ABONOUR R et al. Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 2006; 37: 1103-1108. doi:10.1038/sj.bmt.1705362.
69. ROSENBERG PS, SOCIE G, ALTER BP, GLUCKMAN E. Risk of head and nech squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants, Blood 2005; 105: 67-73. doi:10.1182/blood-2004-04-1652.
70. MASSEROT C, LATOUR RP, ROCHA V, LEBLANC T, RIGO-LET A et al. Head and Neck Squamous Cell Carcinoma in 13 Patients With Fanconi Anemia After Hematopoietic Stem Cell Transplantation. Cancer 2008; 113: 3315-22. doi:10.1002/cncr.23954.
71. SOCIE G, CURTIS RE, DEEG HJ, SOBOCINSKI KA, FILIPOVICH AH et al. New malignant diseases after alloge-neic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348-357.
72. PANIGRAHI S, DAS M, STAGLER D, KONSTANTINI S, GMORI M et al. Development of Secondary Anaplastic Oligoastrocytoma after Matched Unrelated Bone Marrow Transplantation in a Child with Acute Myeloid Leukemia. Acta Haematol 2003; 109: 196-198. doi:10.1159/000070970.
73. FRIEDMAN DL, ROVO A, LEISENRING W, LOCASCIULLI A, FLOWERS ME et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008; 111: 939-944. doi:10.1182/blood-2007-07-099283.
74. SKLAR C, WHITTON J, MERTENS A, STOVALL M, GREEN D et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivors Study. J Clin Endocrinol Metab 2000; 85: 3227-3232. doi:10.1210/ jc.85.9.3227.
75. SANDERS JE, HOFFMEISTER PA, WOOLFREY AE, CARPENTER PA, STORER BE et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 2009; 113: 306-308. doi:10.1182/blood-2008-08-173005.
76. COHEN A, ROVELLI A, MERLO DF, VAN LINT MT, LANINO E et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late EffectsWorking Party Study. J Clin Oncol 2007; 25: 2449-2454. doi:10.1200/JCO.2006.08.9276.
77. ISHIGURO H, YASUDA Y, TOMITA Y, SHINAGAWA T, SHIMIZU T et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004; 89: 5981-5986. doi:10.1210/jc.2004-0836.
78. RIZZO JD, WINGARD JR, TICHELLI A, LEE SJ, VAN LINT MT et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 138-151. doi:10.1016/j.bbmt.2005.09.012.